



MaxiCuma®
172 Folds **More FREE Curcumin**



AGING ISN'T OPTIONAL.
HOW WELL WE AGE MATTERS.

High Potency Curcumin at an Ultra-low Dose

MaxiCuma® Quick Facts:

- 2 Human clinical studies
- Reduces joint pain and stiffness*
- Improves physical function*
- Proven mechanism of action
- Highest free curcumin levels
- Instant cold water dispersible
- No after taste, clean label
- Versatile application formats
- Halal, Kosher, non-GMO and Vegan
- Patented, GRAS Certified
- 100-250 mg dose / day

**These outcomes were statistically significant compared to placebo in the clinical study*

MaxiCuma® is a clinically validated, patented, turmeric ingredient, standardized to 40% curcuminoids. Extracted from turmeric rhizomes (*curcuma longa*) with green ethanol (from sugarcane molasses) and further formulated using proprietary LIMAN™ technology for an enhanced dispersibility and better absorption thereof. The meticulous lecithin microencapsulation process, helps to prevent the degradation of bio actives under the normal physiological conditions, prolong the half-life and improve the overall organoleptic properties.

MaxiCuma® quantifies only the free curcumin (unmetabolized constituent available for bioactivity) in its human pharmacokinetic study, delivering 172 folds higher levels in blood plasma than conventional curcumin extract. It was proven to reduce the degradation of curcumin into its inactive conjugates (metabolites) like glucuronides and sulfides, which are usually eliminated rapidly from the body, due to its water soluble nature.

ENHANCED BIOAVAILABILITY

MaxiCuma®
172 Folds More FREE Curcumin



Active constituent
Free curcumin
component in blood plasma
responsible for biological action

Inactive constituents
Excreted rapidly, producing no biological activity

Published pharmacokinetic study has demonstrated that **MaxiCuma®** delivers **172 folds more** free curcumin levels in the human blood plasma when compared to that of curcumin **95%.***

2.4X
Higher

maximum peak plasma
concentration (Cmax)

1.6X
Hour Faster

time to peak plasma
concentration (Tmax)


3X
Higher

total area under
the curve (AUCt)


Ultra-Low Dose with Superior Efficacy

In a robust randomised placebo controlled clinical trial with 180 subjects for joint health, **MaxiCuma®** 100 and 250mg doses were studied and found to deliver statistically significant results in reducing joint pain, stiffness and improving physical function consistently throughout the supplementation period.


80% Reduction in VAS
(Pain)




79% Reduction in WOMAC Total
(Pain, Stiffness, Physical Function)




131% Improvement in Physical Function
(Treadmill walk)



3.5 times higher Acceptability
(Physician Global Assessment)



Proven Mechanism of Action



Improves anti-inflammatory markers
(IL-10, IL-1 β)



Reduces cartilage damage
(type II collagen, MMP3 & MMP7, glycosaminoglycans)



Reduces inflammatory markers
(COX-2, PGE₂, TNF- α , c-reactive proteins)

— Placebo — MaxiCuma 100 — MaxiCuma 250
* Statistical significance over placebo, $p < 0.0001$ against placebo
Statistical significance of MaxiCuma 250mg over MaxiCuma 100mg, $p < 0.0001$

**<https://www.gavinpublishers.com/article/view/bioavailability-study-of-maxicuma-capsules-versus-micronized-curcumin-capsules-as-a-single-oral-dose-in-fasted-healthy-adult-human-subjects>

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION.
THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

Contact Ennature Biopharma for samples and more information.
ennature@indiaglycols.com | www.ennaturebiopharma.com

© 2024 Ennature Biopharma. All rights reserved

**Ennature**
BIOPHARMA

A DIVISION OF INDIA GLYCOLS LIMITED